|
1.
|
|
9 p, 1.2 MB |
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
/
Fernandez-Perez, María P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Perez-Navarro, Enrique (Hospital Universitario 12 de Octubre (Madrid)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Conteduca, Vincenza (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Font, Albert (Institut Català d'Oncologia) ;
Vázquez-Estévez, Sergio (H. Universitario Lucus Augusti) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Wetterskog, Daniel (Paul O'Gorman Building) ;
Antonarakis, Emmanuel S. (Johns Hopkins University School of Medicine) ;
Mellado, Begoña (Hospital Clínic i Provincial de Barcelona) ;
Fernandez-Calvo, Ovidio (Complejo Hospitalario Universitario Ourense) ;
Méndez-Vidal, María J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Duran, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodriguez Sanchez, Angel (Hospital Universitario de León) ;
Santander, Carmen (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, Maria I. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Puente, Javier (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Tudela, Julian (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martínez, Alberto (Biobanco de la región de Murcia) ;
López-Andreo, Maria J. (SAI-IMIB-Universidad de Murcia) ;
Padilla, José (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Lozano, Rebeca (Instituto de Investigación Biomédica de Málaga) ;
Hervas, David (Instituto de Investigación Sanitaria La Fe) ;
Luo, Jun (Johns Hopkins University School of Medicine) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Attard, Gerhardt (Paul O'Gorman Building) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia-UCAM) ;
Universitat Autònoma de Barcelona
There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). We conducted a phase II trial of enzalutamide in first-line chemo-naïve asymptomatic or minimally symptomatic mCRPC and analyzed the prognostic value of TMPRSS2-ERG and other biomarkers, including circulating tumor cells (CTCs), androgen receptor splice variant (AR-V7) in CTCs and plasma Androgen Receptor copy number gain (AR-gain). [...]
2022 -  10.1002/pros.24469
The Prostate, Vol. 83 (december 2022)
|
|
|
2.
|
|
16 p, 2.1 MB |
Recent therapeutic advances in urothelial carcinoma : A paradigm shift in disease management
/
Bellmunt, J. (Department of Medical Oncology. Beth Israel Deaconess Medical Center and IMIM-PSMAR Lab. Harvard Medical School) ;
Valderrama, B.P. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Puente, J. (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Bolós, M.V. (Pfizer) ;
Laínez, Nuria (Hospital Universitario de Navarra) ;
Vázquez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Climent, Miguel Ángel (Department of Medical Oncology. Valencia Institute of Oncology Foundation) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Arranz, J.Á. (Hospital General Universitario Gregorio Marañón) ;
Durán, Ignacio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Universitat Autònoma de Barcelona
Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. [...]
2022 - 10.1016/j.critrevonc.2022.103683
Critical Reviews in Oncology/Hematology, Vol. 174 (june 2022) , p. 103683
|
|
|
3.
|
|
17 p, 1.2 MB |
Recent advances in the management of patients with non-muscle-invasive bladder cancer using a multidisciplinary approach : Practical recommendations from the spanish oncology genitourinary (sogug) working group
/
Rubio-briones, José (Hospital Vithas Valencia 9 de Octubre) ;
Algaba, Ferran (Institut d'Investigació Biomèdica Sant Pau) ;
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Marcos-Rodríguez, José Antonio (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Climent, Miguel Ángel (Medical Oncology Service. Fundación Instituto Valenciano de Oncología) ;
Gomez-Caamaño, Antonio (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Garcia Vicente, Ana M. (Spanish Oncology Genitourinary) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Rodriguez Antolín, Alfredo (Spanish Oncology Genitourinary) ;
Sanz, Julian (Spanish Oncology Genitourinary) ;
Vera González, Maria Almudena (Spanish Oncology Genitourinary) ;
González-del-Alba, Aránzazu (Spanish Oncology Genitourinary) ;
Conde Moreno, Antonio José (Spanish Oncology Genitourinary) ;
González-Haba, Eva (Spanish Oncology Genitourinary) ;
González-Peramato, Pilar (Spanish Oncology Genitourinary) ;
Linares Espinós, Estefania (Spanish Oncology Genitourinary) ;
López-Beltran, Antonio (Spanish Oncology Genitourinary) ;
Pelechano, Paula (Spanish Oncology Genitourinary) ;
Garrido, Marga (Spanish Oncology Genitourinary) ;
Gironés Sarrió, Regina (Spanish Oncology Genitourinary) ;
Zapatero, Almudena (Spanish Oncology Genitourinary) ;
Arranz Alija, Jose Ángel (Spanish Oncology Genitourinary) ;
Universitat Autònoma de Barcelona
On the basis of the discussion of the current state of research on relevant topics of non-muscle-invasive bladder cancer (NMIBC) among a group of experts of the Spanish Oncology Gen-itourinary (SOGUG) Working Group, recommendations were proposed to overcome the challenges posed by the management of NMIBC in clinical practice. [...]
2021 - 10.3390/cancers13194762
Cancers, Vol. 13 Núm. 19 (October 2021) , p. 4762
|
|
|
4.
|
|
17 p, 1.0 MB |
Management of localized muscle-invasive bladder cancer from a multidisciplinary perspective : Current position of the Spanish oncology genitourinary (Sogug)working group
/
Gomez-Caamaño, Antonio (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Vicente, A.M.G. (Nuclear Medicine Department. University General Hospital) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Antolín, A.R. (Hospital Universitario 12 de Octubre (Madrid)) ;
Sanz, J. (Clínica Universidad de Navarra) ;
González, M.A.V. (Hospital Clínic Universitari (València)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia)
This review presents challenges and recommendations on different aspects related to the management of patients with localized muscle-invasive bladder cancer (MIBC), which were discussed by a group of experts of a Spanish Oncology Genitourinary (SOGUG) Working Group within the framework of the Genitourinary Alliance project (12GU). [...]
2021 - 10.3390/curroncol28060428
Current Oncology, Vol. 28 Núm. 6 (december 2021) , p. 5084-5100
|
|
|
5.
|
|
11 p, 805.4 KB |
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
/
González-del-Alba, Aránzazu (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Méndez-Vidal, M. J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Vazquez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
Castro, E. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia) ;
Lorente, D. (Consorci Hospitalari Provincial de Castelló) ;
Maroto Rey, Pablo. (Institut d'Investigació Biomèdica Sant Pau) ;
Arranz Alija, Jose Ángel (Hospital General Universitario Gregorio Marañón) ;
Universitat Autònoma de Barcelona
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanced prostate cancer allowing a better selection of therapies in each patient. [...]
2021 - 10.1007/s12094-021-02561-5
Clinical & Translational Oncology, Vol. 23 (february 2021) , p. 969-979
|
|
|
6.
|
|
9 p, 341.6 KB |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
/
Conteduca, Vincenza (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wetterskog, Daniel (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Sharabiani, M. T. A. (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Fernandez Perez, M. P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Jayaram, Anuradha (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Romanel, A. (Università di Trento. Centro di Biologia Integrata) ;
Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Casadio, Valentina (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gurioli, Giorgia (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Font Guiteras, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vazquez Estevez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Mellado, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fernandez Calvo, O. (Complejo Hospitalario Universitario de Ourense) ;
Méndez Vidal, M. J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Durán, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodríguez Sánchez, Ángel (Hospital Universitario de León) ;
Santander, C. (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, M. I. (Hospital Regional Universitario de Málaga) ;
Puente, J. (Hospital Clínico San Carlos (Madrid)) ;
Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wingate, Anna (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Dearnaley, David (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ;
Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gonzalez-Billalabeitia, Enrique (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Attard, Gerhardt (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Spanish Oncology Genitourinary Group ;
Universitat Autònoma de Barcelona
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]
2017
Annals of oncology, Núm. 28 (2017) , p. 1508-1516
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
